GoodRx (GDRX) Competitors

GoodRx logo
$3.47 0.00 (-0.12%)
As of 11:08 AM Eastern
This is a fair market value price provided by Massive. Learn more.

GDRX vs. HTFL, SDGR, TDOC, CERT, and HSTM

Should you buy GoodRx stock or one of its competitors? GoodRx's main competitors and comparable companies include Heartflow (HTFL), Schrodinger (SDGR), Teladoc Health (TDOC), Certara (CERT), and HealthStream (HSTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare technology" industry.

How does GoodRx compare to Heartflow?

GoodRx (NASDAQ:GDRX) and Heartflow (NASDAQ:HTFL) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends, media sentiment and earnings.

In the previous week, Heartflow had 27 more articles in the media than GoodRx. MarketBeat recorded 28 mentions for Heartflow and 1 mentions for GoodRx. GoodRx's average media sentiment score of 0.46 beat Heartflow's score of 0.44 indicating that GoodRx is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GoodRx
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Heartflow
4 Very Positive mention(s)
2 Positive mention(s)
15 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

63.8% of GoodRx shares are owned by institutional investors. 5.9% of GoodRx shares are owned by insiders. Comparatively, 7.7% of Heartflow shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

GoodRx has a net margin of 2.07% compared to Heartflow's net margin of -33.11%. GoodRx's return on equity of 7.22% beat Heartflow's return on equity.

Company Net Margins Return on Equity Return on Assets
GoodRx2.07% 7.22% 2.53%
Heartflow -33.11%-20.53%-16.81%

GoodRx has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market. Comparatively, Heartflow has a beta of 2.5, suggesting that its stock price is 150% more volatile than the broader market.

GoodRx presently has a consensus price target of $4.15, suggesting a potential upside of 19.60%. Heartflow has a consensus price target of $60.13, suggesting a potential upside of 27.74%. Given Heartflow's stronger consensus rating and higher probable upside, analysts plainly believe Heartflow is more favorable than GoodRx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GoodRx
3 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.08
Heartflow
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.75

GoodRx has higher revenue and earnings than Heartflow. Heartflow is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GoodRx$796.85M1.49$30.44M$0.0486.75
Heartflow$176.03M23.50-$116.79M-$0.92N/A

Summary

GoodRx and Heartflow tied by winning 8 of the 16 factors compared between the two stocks.

How does GoodRx compare to Schrodinger?

GoodRx (NASDAQ:GDRX) and Schrodinger (NASDAQ:SDGR) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

63.8% of GoodRx shares are owned by institutional investors. Comparatively, 79.1% of Schrodinger shares are owned by institutional investors. 5.9% of GoodRx shares are owned by company insiders. Comparatively, 10.1% of Schrodinger shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

GoodRx has a net margin of 2.07% compared to Schrodinger's net margin of -22.02%. GoodRx's return on equity of 7.22% beat Schrodinger's return on equity.

Company Net Margins Return on Equity Return on Assets
GoodRx2.07% 7.22% 2.53%
Schrodinger -22.02%-18.12%-9.07%

GoodRx has higher revenue and earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GoodRx$796.85M1.49$30.44M$0.0486.75
Schrodinger$255.87M7.53-$103.26M-$0.79N/A

GoodRx has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market. Comparatively, Schrodinger has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

In the previous week, Schrodinger had 6 more articles in the media than GoodRx. MarketBeat recorded 7 mentions for Schrodinger and 1 mentions for GoodRx. Schrodinger's average media sentiment score of 0.72 beat GoodRx's score of 0.46 indicating that Schrodinger is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GoodRx
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Schrodinger
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

GoodRx currently has a consensus target price of $4.15, suggesting a potential upside of 19.60%. Schrodinger has a consensus target price of $26.67, suggesting a potential upside of 3.92%. Given GoodRx's higher possible upside, equities analysts clearly believe GoodRx is more favorable than Schrodinger.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GoodRx
3 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.08
Schrodinger
1 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.38

Summary

GoodRx beats Schrodinger on 8 of the 15 factors compared between the two stocks.

How does GoodRx compare to Teladoc Health?

GoodRx (NASDAQ:GDRX) and Teladoc Health (NYSE:TDOC) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

GoodRx has a beta of 1.66, indicating that its share price is 66% more volatile than the broader market. Comparatively, Teladoc Health has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

In the previous week, Teladoc Health had 5 more articles in the media than GoodRx. MarketBeat recorded 6 mentions for Teladoc Health and 1 mentions for GoodRx. Teladoc Health's average media sentiment score of 0.98 beat GoodRx's score of 0.46 indicating that Teladoc Health is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GoodRx
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Teladoc Health
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

GoodRx presently has a consensus target price of $4.15, suggesting a potential upside of 19.60%. Teladoc Health has a consensus target price of $8.53, suggesting a potential upside of 1.03%. Given GoodRx's higher probable upside, equities analysts clearly believe GoodRx is more favorable than Teladoc Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GoodRx
3 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.08
Teladoc Health
2 Sell rating(s)
11 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.17

GoodRx has higher earnings, but lower revenue than Teladoc Health. Teladoc Health is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GoodRx$796.85M1.49$30.44M$0.0486.75
Teladoc Health$2.53B0.61-$200.32M-$0.86N/A

63.8% of GoodRx shares are held by institutional investors. Comparatively, 76.8% of Teladoc Health shares are held by institutional investors. 5.9% of GoodRx shares are held by company insiders. Comparatively, 0.7% of Teladoc Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

GoodRx has a net margin of 2.07% compared to Teladoc Health's net margin of -6.27%. GoodRx's return on equity of 7.22% beat Teladoc Health's return on equity.

Company Net Margins Return on Equity Return on Assets
GoodRx2.07% 7.22% 2.53%
Teladoc Health -6.27%-11.63%-5.53%

Summary

GoodRx beats Teladoc Health on 9 of the 16 factors compared between the two stocks.

How does GoodRx compare to Certara?

Certara (NASDAQ:CERT) and GoodRx (NASDAQ:GDRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

In the previous week, Certara and Certara both had 1 articles in the media. Certara's average media sentiment score of 1.43 beat GoodRx's score of 0.46 indicating that Certara is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Certara
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
GoodRx
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

GoodRx has higher revenue and earnings than Certara. Certara is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Certara$418.84M4.03-$1.60M-$0.42N/A
GoodRx$796.85M1.49$30.44M$0.0486.75

74.0% of Certara shares are held by institutional investors. Comparatively, 63.8% of GoodRx shares are held by institutional investors. 1.1% of Certara shares are held by insiders. Comparatively, 5.9% of GoodRx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

GoodRx has a net margin of 2.07% compared to Certara's net margin of -16.14%. GoodRx's return on equity of 7.22% beat Certara's return on equity.

Company Net Margins Return on Equity Return on Assets
Certara-16.14% 3.36% 2.31%
GoodRx 2.07%7.22%2.53%

Certara has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, GoodRx has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

Certara presently has a consensus target price of $9.92, indicating a potential downside of 10.34%. GoodRx has a consensus target price of $4.15, indicating a potential upside of 19.60%. Given GoodRx's higher possible upside, analysts plainly believe GoodRx is more favorable than Certara.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Certara
1 Sell rating(s)
7 Hold rating(s)
4 Buy rating(s)
1 Strong Buy rating(s)
2.38
GoodRx
3 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.08

Summary

GoodRx beats Certara on 10 of the 15 factors compared between the two stocks.

How does GoodRx compare to HealthStream?

GoodRx (NASDAQ:GDRX) and HealthStream (NASDAQ:HSTM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, profitability, dividends, analyst recommendations, valuation, institutional ownership and media sentiment.

GoodRx presently has a consensus price target of $4.15, indicating a potential upside of 19.60%. HealthStream has a consensus price target of $36.00, indicating a potential upside of 30.29%. Given HealthStream's higher possible upside, analysts clearly believe HealthStream is more favorable than GoodRx.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GoodRx
3 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.08
HealthStream
0 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

HealthStream has a net margin of 6.25% compared to GoodRx's net margin of 2.07%. GoodRx's return on equity of 7.22% beat HealthStream's return on equity.

Company Net Margins Return on Equity Return on Assets
GoodRx2.07% 7.22% 2.53%
HealthStream 6.25%6.37%4.37%

GoodRx has a beta of 1.66, meaning that its share price is 66% more volatile than the broader market. Comparatively, HealthStream has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

GoodRx has higher revenue and earnings than HealthStream. HealthStream is trading at a lower price-to-earnings ratio than GoodRx, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GoodRx$796.85M1.49$30.44M$0.0486.75
HealthStream$304.06M2.78$18.34M$0.7039.47

In the previous week, GoodRx had 1 more articles in the media than HealthStream. MarketBeat recorded 1 mentions for GoodRx and 0 mentions for HealthStream. HealthStream's average media sentiment score of 1.41 beat GoodRx's score of 0.46 indicating that HealthStream is being referred to more favorably in the news media.

Company Overall Sentiment
GoodRx Neutral
HealthStream Positive

63.8% of GoodRx shares are owned by institutional investors. Comparatively, 69.6% of HealthStream shares are owned by institutional investors. 5.9% of GoodRx shares are owned by insiders. Comparatively, 20.4% of HealthStream shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

GoodRx and HealthStream tied by winning 8 of the 16 factors compared between the two stocks.

Get GoodRx News Delivered to You Automatically

Sign up to receive the latest news and ratings for GDRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GDRX vs. The Competition

MetricGoodRxHealthcare Technology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.19B$1.89B$7.65B$11.69B
Dividend YieldN/A3.89%2.47%4.46%
P/E Ratio86.7741.6733.9329.91
Price / Sales1.495.468.455.70
Price / Cash8.7715.6721.0121.90
Price / Book1.914.684.473.74
Net Income$30.44M-$19.09M$3.51B$393.98M
7 Day Performance-5.04%-8.54%-5.96%-5.71%
1 Month Performance3.15%-6.23%-4.39%-7.03%
1 Year Performance24.23%-11.66%-1.32%-7.26%

GoodRx Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GDRX
GoodRx
3.4509 of 5 stars
$3.47
-0.1%
$4.15
+19.7%
+21.8%$1.19B$796.85M86.77697
HTFL
Heartflow
3.8563 of 5 stars
$56.66
+8.1%
$48.63
-14.2%
+78.3%$4.92B$176.03MN/A843
SDGR
Schrodinger
2.2413 of 5 stars
$33.39
+12.0%
$26.67
-20.1%
+47.0%$2.11B$255.87MN/A850
TDOC
Teladoc Health
1.4273 of 5 stars
$9.01
+2.7%
$8.53
-5.2%
+24.7%$1.77B$2.53BN/A5,600
CERT
Certara
1.8171 of 5 stars
$12.22
+1.4%
$9.92
-18.8%
+35.4%$1.69B$418.84MN/A1,576

Related Companies and Tools


This page (NASDAQ:GDRX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners